SF Bay Area MACS/WIHS Combined Cohort Study

这项研究补充了正在进行的重要的MWCCS范围内的COVID-19疫苗研究 犹豫、顺从和理解。我们的混合方法方法（目标1）将利用MWCCS 疫苗摄取的核心收集，以建立时间途径和细微差别 社会地位，医疗不信任，疫苗利益不信任， 副作用，对企业疫苗暴利的担忧，以及对天然疫苗的偏好， 免疫力我们还将在现有的通用疫苗接受度核心集合的基础上， 制定一项新的工具，评估对疫苗合格性和可获得性的认识; 2） 纳入疫苗宣传工具，以更好地向高风险群体宣传 人口;和3）整合微叙事组件，以探索更细微的差别 影响疫苗接种决策的个人因素，对疫苗的看法， 沟通策略，疫苗分配，和感知疫苗犹豫行为， 家庭和社区。此外，我们建议在附录中收集的数据 在与COVID-19核心调查行为数据整合后， 疫苗改变COVID-19预防行为。这项研究将提供重要的见解， COVID-19疫苗犹豫和接受疫苗的障碍，除了告知 有针对性的沟通策略和干预措施，提高信任度，增加接受度 并打破COVID-19在高风险、老龄化人群中的传播动态， 合并症负担，以MWCCS队列为例。

This study complements the important ongoing MWCCS-wide COVID-19 study of vaccine hesitancy, compliance and uptake. Our mixed-methods approach (Aim 1) will leverage MWCCS core collection of vaccine uptake in order to establish temporal pathways and nuanced relationships between social position, medical mistrust, vaccine benefit mistrust, concerns about side effects, worries about corporate vaccine profiteering, and the preference for natural immunity. We will also build on existing core collection of general vaccine acceptance by 1) developing a new instrument assessing awareness of vaccine eligibility and access; 2) incorporating a vaccine communication instrument to better target messaging to high-risk populations; and 3) integrate a micronarrative component to explore in greater nuance individual-level factors that influence vaccine uptake decision-making, perceptions of vaccine communication strategies, vaccine distribution, and perceived vaccine hesitancy behaviors of the household and community. In addition, the data we propose to collect in the supplement could be leveraged after integration with COVID-19 core survey behavioral data to assess post- vaccine changes to COVID-19 prevention behaviors. This study will offer important insight into COVID-19 vaccine hesitancy and obstacles to vaccine acceptance, in addition to informing targeted communication strategies and intervention efforts that improve trust, increase uptake and break COVID-19 transmission dynamics among high-risk, aging populations with high comorbidity burden, exemplified in the MWCCS cohort.